The clinical value of platelet parameters combined with sFlt-1/PlGF in predicting preeclampsia

Yan, Li; Sun, Lifang; Zheng, Xiuli; Liu, Jingfang; Zheng, Rong; Lv, Yanwei

doi:10.21037/apm-21-1244

Cited by 6 publications

(3 citation statements)

References 30 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Развитие тромбозов ассоциировано с увеличением содержания PLGF у пациентов c антифосфолипидным синдромом [9]. Взаимосвязь между тромбoцитарными параметрами и PLGF показана у женщин с преэклампсией [19], однакo молекулярные механизмы, которые могут лежать в основе данной взаимосвязи, неизвестны и требуют дальнейшего изучения.…”

Section: Discussionunclassified

Proinflammatory biomarkers and platelet aggregation activity in patients with coronary artery disease

Trubacheva,

Kologrivova,

Schnaider

et al. 2024

Bûll. sib. med.

View full text Add to dashboard Cite

Aim. To determine concentrations and identify the relationship of biomarkers (endocan / cell-specific molecule-1, fatty acid binding protein 4 (FABP 4), placental growth factor (PlGF), oncostatin M), with parameters of collageninduced platelet aggregation in patients with coronary artery disease (CAD).Materials and methods. In patients with CAD (n = 51), serum levels of endocan, FABP 4, PlGF, oncostatin M, and platelet aggregation indices (collagen at concentrations of 2 and 10 mmol / l) were determined. Patients were divided into groups with and without high residual platelet reactivity (HRPR). Correlation coefficients between concentrations of proinflammatory biomarkers and platelet aggregation indices were determined in patients of both groups.Results. In patients with HRPR, the concentrations of endocan and PlGF were significantly higher, and the concentrations of FABP4 and oncostatin M were lower than in the first group. In patients with HRPR, a correlation was found between the concentration of endocan and the degree of platelet aggregation in the presence of 2 mmol/ l of collagen (ρ = 0.48; p = 0.01), between the concentration of PlGF and the degree of platelet aggregation in the presence of 10 mmol / l of collagen (ρ = 0.58; p = 0.01), as well as between the concentration of FABP 4 and the size of aggregates at both collagen concentrations (ρ = 0.42; p = 0.03) and (ρ = 0.70; p = 0.01) and the degree of platelet aggregation in the presence of 10 mmol / l of collagen (ρ = 0.43; p = 0.01).Conclusion. In all examined CAD patients, regardless of the residual platelet reactivity, the levels of endocan and FABP 4 increased compared to the reference values. In patients with HRPR, the content of parameters (endocan, PlGF) contributing to plaque growth was elevated, and in patients without HRPR, the levels of platelet-activating factors (FABР 4, oncostatin M) were increased, which determines a personalized approach to prescribing therapy for these groups of patients. In patients with CAD, platelet aggregation indices were associated with concentrations of proinflammatory biomarkers (endocan, PlGF, and FABP 4), which contribute to the development of endothelial dysfunction.

show abstract

Section: Discussionunclassified

Proinflammatory biomarkers and platelet aggregation activity in patients with coronary artery disease

Trubacheva,

Kologrivova,

Schnaider

et al. 2024

Bûll. sib. med.

View full text Add to dashboard Cite

show abstract

“…4 Currently, the soluble fms-like tyrosine kinase 1 (sFlt-1)/placenta growth factor (PlGF) ratio is being investigated as a diagnostic and predictive marker. 5 However, this ratio is mainly applicable to earlyonset preeclampsia (<34 weeks) rather than late-onset preeclampsia (≥34 weeks). In fact, the incidence rate and mortality of late-onset preeclampsia are much higher than those of early-onset preeclampsia.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, the soluble fms‐like tyrosine kinase 1 (sFlt‐1)/placenta growth factor (PlGF) ratio is being investigated as a diagnostic and predictive marker. 5 However, this ratio is mainly applicable to early‐onset preeclampsia (<34 weeks) rather than late‐onset preeclampsia (≥34 weeks). In fact, the incidence rate and mortality of late‐onset preeclampsia are much higher than those of early‐onset preeclampsia.…”

Section: Introductionmentioning

confidence: 99%

Predicting late‐onset preeclampsia by detecting ELABELA content using an immunochromatographic colloidal gold test strip

Yang,

Liu,

Zhang

et al. 2023

J of Clinical Hypertension

View full text Add to dashboard Cite

Preeclampsia is a pregnancy disorder that seriously affects the outcome of mothers and infants and lacks effective prediction and diagnosis methods. ELABELA is the second endogenous ligand of the apelin receptor (APJ) and is associated with the pathogenesis of preeclampsia. In a previous study, the authors found that the downregulation of ELABELA expression is closely related to late‐onset preeclampsia, which may be a marker for the clinical diagnosis of late‐onset preeclampsia. In this study, the authors again collected 120 maternal blood samples, including 60 pregnant women with a medical diagnosis of late‐onset preeclampsia. ELISA results showed that the serum ELABELA concentration in late‐onset preeclampsia pregnant women (12.57 ± 7.77 ng/mL) was significantly lower than that in normal pregnant women (36.99 ± 23.58 ng/mL), which was consistent with previously reported results. Therefore, the authors used an ELABELA monoclonal antibody to label four colloidal gold nanoparticles with different diameters (15, 30, 55, and 150 nm) and developed a transverse‐flow immunochromatographic band for the rapid and accurate detection of serum ELABELA levels. The strip test shows that colloidal gold with a diameter of 30 nm can be used as a good ELABELA detection marker and had more than 90% positive detection effect. Therefore, the authors hope that the colloidal gold strip with ELABELA as the diagnostic index developed by us will be popularized and applied in clinical diagnosis.

show abstract

Platelet count in preeclampsia: a systematic review and meta-analysis

Woldeamanuel¹,

Tlaye²,

Wu³

et al. 2023

American Journal of Obstetrics & Gynecology MFM

View full text Add to dashboard Cite

The clinical value of platelet parameters combined with sFlt-1/PlGF in predicting preeclampsia

Cited by 6 publications

References 30 publications

Proinflammatory biomarkers and platelet aggregation activity in patients with coronary artery disease

Proinflammatory biomarkers and platelet aggregation activity in patients with coronary artery disease

Predicting late‐onset preeclampsia by detecting ELABELA content using an immunochromatographic colloidal gold test strip

Platelet count in preeclampsia: a systematic review and meta-analysis

Contact Info

Product

Resources

About